Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)
2022年11月11日 - 6:33AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
Report of
Foreign Private Issuer
Pursuant to Rule 13a-16 or
15d-16
under the Securities Exchange Act of 1934
For the month of November, 2022
Commission File Number 001-39670
PURETECH HEALTH PLC
(Translation of registrants name into English)
6 Tide
Street, Suite 400
Boston, Massachusetts 02210
(Address of principal executive office)
Indicate by check mark whether
the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F ☒ Form 40-F ☐
Indicate by check mark if the registrant is submitting the Form
6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐
INFORMATION CONTAINED IN THIS REPORT ON FORM 6-K
On November 10, 2022, PureTech Health plc (LSE: PRTC, Nasdaq: PRTC) (the Company) issued a press release noting that Christopher
Viehbacher, Chair of the Companys Board of Directors, has been appointed as President and Chief Executive Officer and a member of the Board of Directors of Biogen Inc. (Nasdaq: BIIB) effective November 14, 2022.
The press release issued by the Company is furnished herewith as Exhibit 99.1 and is incorporated by reference herein.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned,
thereunto duly authorized.
|
|
|
|
|
|
|
|
|
PURETECH HEALTH PLC |
|
|
|
Date: November 10, 2022 |
|
By: |
|
/s/ Daphne Zohar |
|
|
|
|
Name: |
|
Daphne Zohar |
|
|
|
|
Title: |
|
Chief Executive Officer |
Puretech Health (PK) (USOTC:PTCHF)
過去 株価チャート
から 6 2024 まで 7 2024
Puretech Health (PK) (USOTC:PTCHF)
過去 株価チャート
から 7 2023 まで 7 2024
Real-Time news about Puretech Health PLC (PK) (その他OTC): 0 recent articles
その他のPuretech Health Plcニュース記事